
MHE Staff
Articles by MHE Staff


Expert William J. Mallon, M.D., discusses the most-common eye diseases seen in practice.


Authors of a review say biosimilars would improve treatment, not just reduce cost.

Real-world evidence from 67 patients recently found benefits for those with diabetic macular edema who switched to Eylea from Lucentis.

Whether the OCM has worked out is debatable, but it has apparently encouraged the use of biosimilar versions of filgrastim.

Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.

The physician-led communication training program is now available through a virtual-only experience as health care organizations adapt to the changing environment surrounding COVID-19.

Botco.ai’s AI-powered intelligent chat solution automatically addresses questions regarding COVID-19, scheduling visits, franchising and more.

Researchers reviewed the evidence of the association between vitamin D and multiple sclerosis.

A recent study found 64% of patients with psoriatic arthritis who had tried at least one biologic stayed with Cosentyx for the entire study period.


Dovato lets adults with HIV reduce the number of antiretroviral therapies they take, while maintaining efficacy and a high barrier to resistance comparable to tenofovir-based regimens.

Double-blind study will compare Rebif-remdesivir combination with remdesivir-alone in hospitalized COVID-19 patients

The highly respected healthcare industry veteran will bring his signature team building skills, track record of double-digit revenue growth and subject matter expertise in diabetes.

Many are anxious or down but finding silver linings amidst challenges; essential workers and boomers are faring better than most.

Content of this article was sponsored by Arbor Pharmaceuticals, LLC. Copyright 2020. This Managed Healthcare Executive® publication provides key information regarding a review by Faraone, et al, which was originally published in the Journal of the American Academy of Child & Adolescent Psychiatry (doi: 10.1016/j.jaac.2019.06.012). The authors of the original review are Stephen V. Faraone, PhD; Anthony L. Rostain, MD; C. Brendan Montano, MD; Oren Mason, MD; Kevin M. Antshel, PhD; Jeffrey H. Newcorn, MD. Please consult the full published review for complete information.

As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Third of three parts. See more in our Surveys tab.

As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Second of three parts. See more in our Surveys tab.

As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. First of three parts. See more in our Surveys tab.

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

An experimental coronavirus vaccine called AZD1222 triggered an immune response against COVID-19 in study participants, and it has only minor side effects.

When universal testing was implemented, 40% of the tested residents were positive for SARS-CoV-2.

The Network’s Board of Trustees has appointed Mansue as the new president and CEO, effective September 1. She will succeed John DiAngelo, who announced his intention to retire in January following his 20-year tenure with the organization.

The higher case-fatality rate could be because of low resting rates, a greater number of deaths, or both,

Drug development in key areas of unmet need hit milestones this week, with Biogen, AstraZeneca, and Jaguar Health announcing regulatory steps with the FDA.


Federal agency is dispatching Quality Improvement Organizations to hotspots.

The new plan, called Gravie Comfort, offers 100% coverage on most common healthcare services, including preventive care, primary care, specialist visits, labs and imaging, generic prescriptions, online care, and more – all at a cost comparable to most traditional group health plans.

Lowering the age and smoking history standards would result in substantially more Blacks and women being eligible for screening.
